Benitec Biopharma
BNTC
7 hedge funds and large institutions have $1.23M invested in Benitec Biopharma in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
17% more funds holding
Funds holding: 6 → 7 (+1)
0% less ownership
Funds ownership: 0% → 0% (-0%)
33% less capital invested
Capital invested by funds: $1.85M → $1.23M (-$614K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$322K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$32.1K |
| 3 |
Morgan Stanley
New York
|
+$23.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Highbridge Capital Management
New York
|
-$1.33M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$92.2K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$40K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$4.78K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HCM
1
Highbridge Capital Management
New York
| $647K | -$1.33M | -1,952 | -65% |
|
|
SFM
2
Sphera Funds Management
Tel Aviv,
Israel
| $294K | +$322K | +471 | New |
|
|
3
Morgan Stanley
New York
| $141K | +$23.2K | +34 | +17% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $84K | -$92.2K | -135 | -50% |
|
5
Renaissance Technologies
New York
| $32K | – | – | – |
|
|
6
Citadel Advisors
Miami,
Florida
| $30K | +$32.1K | +47 | New |
|
|
7
UBS Group
Zurich,
Switzerland
| $5K | -$4.78K | -7 | -47% |
|
|
WS
8
Wedbush Securities
Los Angeles,
California
| – | -$40K | -78 | Closed |
|
BNTC Hedge Fund Activity: Q3 2018 in Review
7 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Benitec Biopharma (BNTC) for Q3 2018, worth a combined $1.23M — down 33% from $1.85M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BNTC positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Sphera Funds Management, opening a new position worth an estimated $322K. The largest seller was Highbridge Capital Management, cutting an estimated $1.33M.
- 7 institutional investors held Benitec Biopharma (BNTC) as of Q3 2018, up from 6 in Q2 2018.
- Funds reported $1.23M of Benitec Biopharma stock for Q3 2018, down 33% quarter-over-quarter.
- 2 funds opened new Benitec Biopharma positions in Q3 2018 and 1 closed out, a net change of +1 holder.
- The largest Benitec Biopharma buyer in Q3 2018 was Sphera Funds Management, an estimated $322K added.
- The largest Benitec Biopharma seller in Q3 2018 was Highbridge Capital Management, an estimated $1.33M sold.
Based on aggregated 13F filings for Q3 2018.